Indivior UK has entered into a strategic collaboration with Addex Pharma, a wholly-owned subsidiary of Addex Therapeutics, in the field of GABAB positive allosteric modulators (PAMs).
Indivior said GABAB PAMs had demonstrated preclinical efficacy and tolerability in animal models for alcohol use disorder (AUD) and cocaine use disorder (CUD).
Indivior said the collaboration included an exclusive global licence to lead candidate ADX71441, which was a novel, first-in-class, oral, small molecule and was expected to enter Phase 1 trials in 2018.
The collaboration also includes exclusive global licence to backup GABAB PAM compounds, as well as a research collaboration focused on discovering additional GABAB PAMs.
The Addex GABAB program was recently awarded a $5.3m grant by the National Institute on Drug Abuse to support the development of ADX71441 in CUD.
Under the terms of the agreement, Indivior is making an upfront payment to Addex of $5m, and will also invest in research funding over the next two years to discover additional GABAB PAM compounds commercially-viable to treat addiction.
Potential milestone payments to Addex could total $330m over time if all development, regulatory and sales goals are achieved.